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Abstract
Background—Studies on associations between periconceptional cannabis exposure and birth 
defects have mainly relied on self-reported exposure. Therefore, the results may be biased due to 
underreporting of the exposure. The aim of this study was to quantify the potential effects of this 
form of exposure misclassification.
Methods—Using multivariable logistic regression, we re-analyzed associations between 
periconceptional cannabis use and 20 specific birth defects using data from the National Birth 
Defects Prevention Study from 1997–2005 for 13 859 case infants and 6556 control infants. For 
seven birth defects, we implemented four Bayesian models based on various assumptions 
concerning the sensitivity of self-reported cannabis use to estimate odds ratios (ORs), adjusted for 
confounding and underreporting of the exposure. We used information on sensitivity of self-
reported cannabis use from the literature for prior assumptions.
Results—The results unadjusted for underreporting of the exposure showed an association 
between cannabis use and anencephaly (posterior OR 1.9 [95% credible interval (CRI) 1.1, 3.2]) 
which persisted after adjustment for potential exposure misclassification. Initially, no statistically 
significant associations were observed between cannabis use and the other birth defect categories 
studied. Although adjustment for underreporting did not notably change these effect estimates, 
cannabis use was associated with esophageal atresia (posterior OR 1.7 [95% CRI 1.0, 2.9]), 
diaphragmatic hernia (posterior OR 1.8 [95% CRI 1.1, 3.0]) and gastroschisis (posterior OR 1.7 
[95% CRI 1.2, 2.3]) after correction for exposure misclassification.
Conclusions—Underreporting of the exposure may have obscured some cannabis-birth defect 
associations in previous studies. However, the resulting bias is likely to be limited.
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Valid measurement of exposures, outcomes, and potential confounders is essential in 
epidemiologic research to prevent information bias.1 In case-control studies, non-differential 
or differential misclassification may be present when exposure information is collected after 
the outcome has occurred. Under certain conditions, non-differential misclassification of a 
dichotomous variable biases results towards the null value.2,3 Differential misclassification, 
on the other hand, may lead to either underestimation or overestimation of the true effect.1 
Multiple methods to correct for potential biases due to misclassification in observational 
studies have recently been published.4–7 Although misclassification frequently occurs in 
epidemiologic research, methods to quantify the resulting bias are rarely used or reported for 
a variety of reasons, including complexity of reporting and a lack of demand.4,8 However, 
this does not justify lack of attention to potential bias in observed exposure-outcome 
associations that may result from ignoring misclassification.9,10 In this paper, we present a 
case study in which adjustments for underreporting of the exposure of interest were made by 
means of Bayesian methods.
Although maternal cannabis use generally does not appear to be associated with the 
occurrence of major birth defects,11–13 increased risks of gastroschisis,14 isolated simple 
ventricular septal defects (VSDs),15 and anencephaly13 have been reported after prenatal 
cannabis exposure. As most of these studies used a case-control design and all used self-
reported modes of data collection for exposure assessment (either maternal interviews or 
medical chart reviews), non-differential or differential misclassification of cannabis use may 
have occurred and subsequently may have biased the results. It is very likely that the use of 
cannabis was underestimated in these studies, because some subjects would have falsely 
denied use for fear of judgment or prosecution.16 Although misclassification of cannabis use 
during pregnancy was generally acknowledged, no attempts were made to quantify the effect 
of underreporting on cannabis-birth defect associations. In this study, we used data from the 
National Birth Defects Prevention Study (NBDPS) to estimate odds ratios and interval 
estimates adjusted for underreporting of the exposure for the associations between 
periconceptional cannabis use and selected birth defects.
METHODS
Data
The NBDPS is a multi-site population-based case-control study of more than 30 types of 
major birth defects that started enrollment of women with an estimated date of delivery on 
or after October 1, 1997.17 Case infants (live born, stillborn, or induced abortions) were 
identified using existing birth defects surveillance systems in Arkansas, California, Georgia, 
Iowa, Massachusetts, New Jersey, New York, North Carolina, Texas, and Utah. Information 
on birth defects abstracted from hospital records was reviewed by a clinical geneticist at 
each study center to determine eligibility. The methods used for case classification in the 
NBDPS have been described in detail elsewhere.18 Control infants were randomly selected 
from all live-born infants without any major birth defect from the same geographical area 
and time period using either hospital birth records (Arkansas, California, Georgia 1997–
2000, New York, and Texas) or birth certificates (Georgia 2001–2005, Iowa, Massachusetts, 
New Jersey, North Carolina, and Utah). Computer-assisted telephone interviews were 
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conducted with the mothers of case and control infants between 6 weeks and 24 months after 
the estimated date of delivery, including questions on demographic factors, medical and 
pregnancy history, lifestyle, and occupation. For the time period of interest, the interview 
participation rate was 69% for case mothers and 66% for control mothers.
In this study, exposure to cannabis was defined as any reported use of marijuana or hashish 
in the period from 1 month before pregnancy to the end of the third month of pregnancy 
(periconceptional period). Only case and control infants whose mothers did not report use of 
any illicit drugs in the 3 months before pregnancy and during the entire index pregnancy, 
were considered unexposed.
The current study included case and control infants born from October 1, 1997 through 
December 31, 2005, whose mothers completed the interview (n = 18 745 and 6703, 
respectively). This dataset overlaps to a large extent with the dataset used by van Gelder et 
al. to study associations between periconceptional illicit drug use and birth defects,13 but it 
contains 2 additional years of data. Only case infants diagnosed with one of the 20 birth 
defect categories selected by van Gelder et al.13 (n = 14 429) were included in this study. 
Analogous to our previous study, infants born to women who reported preexisting diabetes 
type 1 or type 2 (298 cases and 39 controls) were excluded because of the strong association 
with major birth defects,19 as well as infants only exposed to other types of illicit drugs (84 
cases and 30 controls) or with missing information on illicit drug exposure (188 cases and 
78 controls) because of our exposure definition. Eventually, we analyzed data on 13 859 
case infants and 6556 control infants.
Statistical analysis
We first repeated our earlier analyses13 using the updated dataset. In these analyses, 
multivariable logistic regression techniques were used to calculate adjusted odds ratios 
(aORs) and 95% confidence intervals (CIs) for periconceptional cannabis use and each of 
the 20 selected birth defects. The same confounder set used in the previous study, consisting 
of maternal age at delivery, race/ethnicity, level of education, smoking in the 
periconceptional period, binge drinking in the periconceptional period (≥4 drinks per 
episode), prepregnancy body mass index, and any use of folic acid or multivitamins 
containing folic acid in the month before pregnancy or in the first month of pregnancy, was 
included in all current multivariable analyses. The re-analysis was performed using SPSS 
version 17.0 for Windows (SPSS Inc., Chicago, IL).
As data on the validity of the interview data on periconceptional cannabis use were not 
available, we used information on sensitivity of self-reports from the literature. We are not 
aware of any studies that provide information on accuracy of cannabis reporting among 
mothers of infants with birth defects. However, we identified 5 studies which determined the 
sensitivity of interview data on cannabis use among pregnant and postpartum women (Table 
1).20–24 These studies reported sensitivities ranging from 0.58 to 0.82. Because falsely 
reporting cannabis use is very unlikely, we assumed specificity to be 1.00 in all analyses. 
These parameters were used in Bayesian models to adjust the cannabis-birth defect 
associations for non-differential or differential underreporting. These analyses were 
performed using WinBUGS version 1.4 from within R version 2.12.2 for Windows25 for 7 
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birth defect groups: all defects that had an elevated OR for periconceptional cannabis use in 
the frequentist re-analysis (i.e. anencephaly, esophageal atresia, diaphragmatic hernia, and 
gastroschisis), 1 defect with a decreased OR for periconceptional cannabis use 
(hypospadias), 1 defect that has been associated with periconceptional cannabis use in 
previous studies but not in our re-analysis (perimembranous VSD), and 1 defect with a 
relatively large case group that was not associated with periconceptional cannabis use (cleft 
lip ± cleft palate).
Following the framework of MacLehose et al.,6 we conducted Bayesian uncertainty analyses 
conditional on prior hypotheses generated from published studies. In short, 3 models, an 
outcome model, an exposure model, and a measurement model, were jointly estimated, 
which allowed simultaneous imputation of the true periconceptional cannabis exposure 
status and estimation of its effect on the risk of the selected birth defects. In the outcome 
model, the odds of an infant having the selected birth defect was modeled with a logistic 
regression model conditional on the (unknown) periconceptional cannabis exposure status 
and the potential confounders assuming no interaction between cannabis use and other 
factors:
where BDi is case/control status, β1 is the effect of periconceptional cannabis use, canitrue is 
the unobserved true periconceptional cannabis exposure status, and θ is a vector of effects of 
the potential confounders in the vector zi’. We used a non-informative normal distribution 
with mean = 0 and variance = 106 for the prior distribution of the intercept. Informative 
priors were placed on the remaining parameters (Table 2). These prior distributions were 
informed using prior studies, which were discussed among a panel of experienced 
researchers in the field of birth defects epidemiology, consisting of 2 of the authors and 3 
experts outside the study team. As an example, we assumed folic acid supplementation to 
have no additional protective effect on folate-sensitive birth defects (normal distribution, 
mean = 0, variance = 0.13), because all pregnant women in our study were exposed to folic 
acid through food fortification.26 Priors on coefficients for which no information from 
previous studies was available and the prior on the effect of periconceptional cannabis use 
on the risk of birth defects were kept relatively vague (normal distribution, mean = 0, 
variance = 0.67; corresponding to a prior OR of 1.0 with a 95% credible interval of [0.2, 
5.0]) as we were uncertain about the magnitude of the ORs for these associations.
In the exposure model, we modeled the probability of true exposure to cannabis in the 
periconceptional period conditional on a set of predictors:
where ω is a vector of the effects of the predictors in zi’. The set of predictors consisted of 
all potential confounders and paternal cannabis use, which is highly predictive of maternal 
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illicit drug use.27,28 However, as is discussed by MacLehose et al.,6 it is difficult to inform 
priors for parameter estimates because the outcome of interest, true exposure to cannabis, is 
generally not observed in studies. Therefore, we also placed vague priors (normal 
distribution, mean = 0, variance = 0.67) on the coefficients in this model.
Finally, in the measurement model we modeled the probability of reporting periconceptional 
cannabis use during the interview dependent on the true (but unobserved) exposure status 
and the case/control status, which allowed us to introduce differential misclassification. 
Because we assumed specificity to be 1.00, we could simplify the measurement model used 
by MacLehose et al.6 to:
Here caniint is the periconceptional cannabis exposure status the woman reported in the 
interview, α0 is the sensitivity of reported cannabis use among control mothers, , and α1 is 
the sensitivity of reported cannabis use among case mothers. The exposure and measurement 
models were used to impute values of canitrue in a way similar to that used with Bayesian 
missing data techniques.6 These imputed values were then used to estimate the associations 
between periconceptional cannabis use and the selected birth defects.
To quantify the potential effects of underreporting of the exposure on the cannabis-birth 
defect associations observed, we implemented four scenarios that specified α0 and α1 in the 
measurement model. In Scenario 1, the reference scenario, we assumed sensitivity to equal 
1.00 (no correction for underreporting), which resulted in a standard Bayesian logistic 
regression model. Scenario 2 is based on the assumption that cannabis exposure status was 
non-differentially misclassified with a sensitivity fixed at 3 different values: 0.80, 0.65, and 
0.50. In case-control studies of birth defects, there is evidence that maternal reporting is not 
affected by pregnancy outcome.29,30 However, since recall bias cannot be excluded, it was 
assumed that the cannabis exposure status was differentially misclassified for Scenario 3, 
with the assumed sensitivity to be 0.05 or 0.10 lower among controls than the fixed values 
of 0.80 and 0.65 among cases. Scenario 4 was based on the assumption that the sensitivities 
used in the measurement model are not exactly known. For the prior distribution of the 
sensitivity, a beta distribution (α = 15, β = 6.5) was chosen with prior parameters selected to 
reflect a priori beliefs concerning reported cannabis use, i.e. sensitivity with a mean of 0.7 
and a standard deviation of 0.1. The values for sensitivity among cases and controls were 
assumed not to be correlated.
We conducted a sensitivity analysis to determine the influence of our prior assumptions in 
the exposure and outcome models by placing vague priors on all coefficients in every model. 
All models were fitted using Markov chain Monte Carlo algorithms, which were run for 20 
000 iterations with the first 1000 iterations excluded as a burn-in period. We ran three chains 
from different initial positions; convergence was monitored with trace plots and the Gelman-
Rubin statistic. After the burn-in period, the iterations of the algorithm were random draws 
from the posterior distributions of interest, of which the median was exponentiated to obtain 
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the OR of interest. We exponentiated the 2.5th and 97.5th percentile of the random draws to 
obtain 95% posterior credible intervals (CRIs). To provide a measure of precision of the 
CRIs, we calculated the half width ratio by dividing the half-width of the CRI by the 
median. The R script and model specifications used are shown in Appendix S2.
RESULTS
A total of 825 mothers (4.0%) reported use of cannabis in the periconceptional period: 4.1% 
of the case mothers and 3.8% of the control mothers. The ORs for periconceptional cannabis 
use adjusted for confounding observed in the original and updated datasets for each of the 
birth defects studied are shown in Table 3. In general, the results from the replication 
analyses were comparable with the ORs reported earlier.13 In the updated dataset, 
periconceptional cannabis use was more strongly associated with anencephaly (aOR = 2.2 
[95% CI 1.3, 3.7]) and indications were found for associations with esophageal atresia (aOR 
= 1.4 [95% CI 0.8, 2.4]), diaphragmatic hernia (aOR = 1.4 [95% CI 0.9, 2.2]), and 
gastroschisis (aOR = 1.2 [95% CI 0.9, 1.7]). No associations were observed between 
cannabis use in the periconceptional period and any of the other 16 birth defect categories.
In the Bayesian assessment, the observed ORs for the associations between the potential 
confounders and the selected birth defects (Appendix S3) were for the most part consistent 
with the prior specifications (Table 2). All models converged relatively quickly. The 
posterior ORs and 95% CRIs for the associations between periconceptional cannabis use and 
the 4 selected birth defects with elevated ORs in the replication analyses are shown in Table 
4. After adjustment for non-differential underreporting (Scenario 2), we observed 
associations between cannabis use in the periconceptional period and anencephaly with 
posterior ORs of 2.0 [95% CRI 1.2, 3.4], 2.1 [95% CRI 1.2, 3.4], and 2.0 [95% CRI 1.2, 3.3] 
for assumed sensitivities of 0.80, 0.65, and 0.50, respectively (Figure 1a). In addition, 
periconceptional cannabis use seemed to be associated with esophageal atresia, 
diaphragmatic hernia, and gastroschisis with posterior ORs of 1.6 [95% CRI 0.9, 2.5], 1.8 
[95% CRI 1.2, 2.7], and 1.6 [95% CRI 1.2, 2.2], respectively (Scenario 2, sensitivity 0.50). 
As expected, the elevated posterior ORs were slightly diminished compared to Scenario 2 
after adjusting for the possibility of recall bias (Scenario 3), but still resulted in increased 
ORs for anencephaly, diaphragmatic hernia, and gastroschisis. Estimates from Scenario 4, 
which treated the sensitivity as unknown, showed increased posterior ORs after 
periconceptional cannabis use for anencephaly (OR = 2.1 [95% CRI 1.2, 3.6]), esophageal 
atresia (OR = 1.7 [95% CRI 1.0, 2.9]), diaphragmatic hernia (OR = 1.8 [95% CRI 1.1, 3.0]), 
and gastroschisis (OR = 1.7 [95% CRI 1.2, 2.3]) with wider CRIs compared with Scenario 1.
For hypospadias, perimembranous VSD, and cleft lip ± cleft palate, no statistically 
significant posterior ORs were observed after adjustment for underreporting in all Scenarios 
studied (Table 5). However, the risk of hypospadias seemed to be decreased after adjustment 
for differential misclassification with the lowest value being 0.7 (95% CRI 0.5, 1.0; 
sensitivity among cases 0.80, sensitivity among controls 0.70). Again, the CRIs were wider 
in Scenario 4 than in the other Scenarios.
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The results of the sensitivity analyses indicated that placing vague priors on the coefficients 
in the outcome and exposure models did not change the results substantially (Appendix S4). 
However, the posterior ORs for the association between periconceptional cannabis use and 
anencephaly were slightly higher with wider posterior CRIs in the sensitivity analysis 
compared with the main analysis.
COMMENTS
The results from our frequentist replication analysis were very similar to the results reported 
previously.13 We applied Bayesian methods to estimate the potential effects of exposure 
misclassification on cannabis-birth defects associations because the joint estimation of the 
outcome, exposure, and measurement model is relatively straightforward in Bayesian 
inference, especially when compared with frequentist inference.6 After adjustments for 
underreporting of the exposure, the OR estimates for the associations between 
periconceptional cannabis use and the 7 selected birth defects did not change considerably 
compared with the naïve Scenario assuming no misclassification and were very consistent 
across all Scenarios, even with sensitivities as low as 0.50. However, we found statistically 
significant associations between periconceptional cannabis use and the occurrence of 
anencephaly and gastroschisis in all Scenarios studied. In addition, increased odds ratios for 
esophageal atresia and diaphragmatic hernia were observed among infants exposed to 
cannabis in the periconceptional period in Scenarios 2 and 4 and in some cases of Scenario 
3.
Although the differences with the naïve Scenario were small, the OR estimates obtained in 
Scenario 2, which corrected for non-differential misclassification with sensitivity as a 
known constant, were in the expected direction for most defects.2,3 For hypospadias, 
however, the corrected ORs seem to move towards the null, indicating that the commonly-
used assumption that non-differential misclassification results in smaller effect estimates is 
not sufficient.
In case of recall bias, one would expect associations to be biased away from the null (i.e. an 
overestimation of the effect). However, since the sensitivity among cases was also not 
assumed to be perfect in Scenario 3, the ORs observed in this Scenario do not necessarily 
have to be lower than those observed in Scenario 1. When comparing Scenarios 2 and 3 for 
the fixed sensitivity values of 0.80 and 0.65 (similar to the sensitivity among cases in 
Scenario 3), we indeed observed slightly lower ORs after adjustment for differential 
misclassification.
Ideally, data obtained from a validation study conducted within the NBDPS should be used 
to quantify sensitivity and specificity of self-reported cannabis exposure status as these 
measures may vary across settings. However, due to the retrospective study design, we 
could only use external validation data, which were collected years before the start of the 
NBDPS in different populations (Table 1). Because participants in the validation studies 
were told about the testing procedures which may have increased reporting of exposure, we 
used somewhat lower values for sensitivity in our analyses than those observed in these 
studies. As a consequence, Scenario 4, which treated sensitivity as unknown, is of particular 
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interest in this case, although the choice for a prior distribution for this parameter may be 
debated. We applied the same beta distribution to both the sensitivity among cases and 
controls, which were assumed to be independent. In future work, models allowing 
correlation between the sensitivities, as proposed by Greenland and Gustafson,31 could be 
applied. In Scenario 4, the posterior ORs observed were larger than those produced in the 
other Scenarios, which is comparable with the pattern observed by MacLehose et al.6
Although the OR estimates adjusted for underreporting of cannabis use in the 
periconceptional period followed expectation with regard to the direction of the resulting 
bias, the results only slightly changed after correction for misclassification. This may have 
been due to the relatively low exposure prevalence in the study population. Larger changes 
in effect estimates for the association between periconceptional maternal smoking, which is 
much more common than cannabis use, and orofacial clefts were observed in a study using 
the same Bayesian methods,6 adding credibility to this explanation. However, despite the 
limited size of the changes, some associations that were not statistically significant in the 
naïve models reached statistical significance after correction for underreporting, suggesting 
that some associations may be overlooked if exposure misclassification is not taken into 
account.
When accounting for any source of bias, adjustments lead to a widening of intervals. In the 
Scenarios with fixed sensitivity values, we did not observe this widening of CRIs as we did 
not incorporate additional uncertainty into the models. However, in Scenario 4, in which 
additional uncertainty with respect to sensitivity values was incorporated, we did see the 
expected widening of the CRIs.
In addition to the use of external validation data, our approach has other limitations as well. 
We assumed that the specificity of the interview was 1.00 and that no measurement error 
was present in the confounding and outcome variables, so we cannot rule out that other 
types of error biased our results. The models used in this framework could be adapted to 
incorporate imperfect specificity of the measurement instrument and other sources of bias if 
reasonable prior values are available.6 Furthermore, we excluded infants born to women 
with preexisting diabetes as these were omitted from our previous study,13 which we wanted 
to mirror as closely as possible. Extensions to the work presented here could consist of 
including this group of subjects, as well as additional analyses on cases with isolated defects 
only and subjects without a positive family history of the birth defect under study.
Exposure misclassification may have a serious impact on the validity of epidemiologic 
studies. The best solution is to measure exposures without error, but this is often impossible. 
Sensitivity analyses, such as the Bayesian approach presented in this paper, may provide 
insight into the possible impact of exposure misclassification on the effect estimates. In the 
case of cannabis-birth defect associations, underreporting of the exposure may have 
obscured other possible associations, including those between periconceptional cannabis use 
and the occurrence of esophageal atresia, diaphragmatic hernia, and gastroschisis. 
Furthermore, the analyses indicated that it is unlikely that the association between exposure 
to cannabis in the periconceptional period and anencephaly observed in the standard logistic 
regression analysis can be explained by exposure misclassification. However, the OR 
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estimates only slightly changed after correction for misclassification. As stated previously,6 
it is doubtful that further case-control studies will be able to answer the question whether 
these associations are true or not without improvements in the methods of data collection, 
such as completing interviews as shortly after delivery as possible32 and the use of a 
Certificate of Confidentiality.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
ACKNOWLEDGEMENTS
The Centers for Disease Control and Prevention provided funding for the National Birth Defects Prevention Study. 
MMHJvG was supported by grant 021.001.008 from the Netherlands Organisation for Scientific Research.
REFERENCES
1. Rothman, KJ.; Greenland, S.; Lash, TL. Validity in epidemiologic studies. In: Rothman, KJ.; 
Greenland, S.; Lash, TL., editors. Modern epidemiology. 3rd. Lippincott Williams & Wilkins; 
Philadelphia: 2008. p. 128-147.
2. Jurek AM, Greenland S, Maldonado G, Church TR. Proper interpretation of non-differential 
misclassification effects: expectations vs observations. International Journal of Epidemiology. 2005; 
34:680–687. [PubMed: 15802377] 
3. Lash, TL.; Fox, MP.; Fink, AK. Misclassification. In: Lash, TL.; Fox, MP.; Fink, AK., editors. 
Applying quantitative bias analysis to epidemiologic data. Springer; Dordrecht: 2009. p. 79-108.
4. Lash TL, Fink AK. Semi-automated sensitivity analysis to assess systematic errors in observational 
data. Epidemiology. 2003; 14:451–458. [PubMed: 12843771] 
5. Steenland K, Greenland S. Monte Carlo sensitivity analysis and Bayesian analysis of smoking as an 
unmeasured confounder in a study of silica and lung cancer. American Journal of Epidemiology. 
2004; 160:384–392. [PubMed: 15286024] 
6. MacLehose RF, Olshan AF, Herring AH, Honein MA, Shaw GM, Romitti PA. Bayesian methods 
for correcting misclassification: an example from birth defects epidemiology. Epidemiology. 2009; 
20:27–35. [PubMed: 19234399] 
7. Chu R, Gustafson P, Le N. Bayesian adjustment for exposure misclassification in case-control 
studies. Statistics in Medicine. 2010; 29:994–1003. [PubMed: 20087839] 
8. Jurek AM, Maldonado G, Greenland S, Church TR. Exposure-measurement error is frequently 
ignored when interpreting epidemiologic study results. European Journal of Epidemiology. 2006; 
21:871–876. [PubMed: 17186399] 
9. Diamond EL, Lilienfeld AM. Effects of errors in classification and diagnosis in various types of 
epidemiological studies. American Journal of Public Health and the Nation’s Health. 1962; 
52:1137–1144.
10. Reade-Christopher SJ, Kupper LL. Effects of exposure misclassification on regression analyses of 
epidemiologic follow-up study data. Biometrics. 1991; 47:535–548. [PubMed: 1912260] 
11. Witter FR, Niebyl JR. Marijuana use in pregnancy and pregnancy outcome. American Journal of 
Perinatology. 1990; 7:36–38. [PubMed: 2294909] 
12. Shaw GM, Velie EM, Morland KB. Parental recreational drug use and risk for neural tube defects. 
American Journal of Epidemiology. 1996; 144:1155–1160. [PubMed: 8956628] 
13. Van Gelder MMHJ, Reefhuis J, Caton AR, Werler MM, Druschel CM, Roeleveld N. Maternal 
periconceptional illicit drug use and the risk of congenital malformations. Epidemiology. 2009; 
20:60–66. [PubMed: 19057385] 
14. Torfs CP, Velie EM, Oechsli FW, Bateson TF, Curry CJ. A population-based study of 
gastroschisis: demographic, pregnancy, and lifestyle risk factors. Teratology. 1994; 50:44–53. 
[PubMed: 7974254] 
van Gelder et al. Page 9
Paediatr Perinat Epidemiol. Author manuscript; available in PMC 2015 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
15. Williams LJ, Correa A, Rasmussen S. Maternal lifestyle factors and risk for ventricular septal 
defects. Birth Defects Research Part A Clinical and Molecular Teratology. 2004; 70:59–64.
16. Kilpatrick B, Howlett M, Sedgwick P, Ghodse AH. Drug use, self report and urinalysis. Drug and 
Alcohol Dependence. 2000; 58:111–116. [PubMed: 10669061] 
17. Yoon PW, Rasmussen SA, Lynberg MC, Moore CA, Anderka M, Carmichael SL, et al. The 
National Birth Defects Prevention Study. Public Health Reports. 2001; 116(Suppl.1):32–40. 
[PubMed: 11889273] 
18. Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA. Guidelines for 
case classification for the National Birth Defects Prevention Study. Birth Defects Research Part A 
Clinical and Molecular Teratology. 2003; 67:193–201.
19. Correa A, Gilboa SM, Besser LM, Botto LD, Moore CA, Hobbs CA, et al. Diabetes mellitus and 
birth defects. American Journal of Obstetrics and Gynecology. 2008; 199:237.e1–237.e9. 
[PubMed: 18674752] 
20. Hingson R, Zuckerman B, Amaro H, Frank DA, Kayne H, Sorenson JR, et al. Maternal marijuana 
use and neonatal outcome: uncertainty posed by self-reports. American Journal of Public Health. 
1986; 76:667–669. [PubMed: 3518499] 
21. Frank DA, Zuckerman BS, Amaro H, Aboagye K, Bauchner H, Cabral H, et al. Cocaine use during 
pregnancy: prevalence and correlates. Pediatrics. 1988; 82:888–895. [PubMed: 3186380] 
22. Zuckerman B, Frank DA, Hingson R, Amaro H, Levenson SM, Kayne H, et al. Effects of maternal 
marijuana and cocaine use on fetal growth. New England Journal of Medicine. 1989; 320:762–
768. [PubMed: 2784193] 
23. Jacobson SW, Jacobson JL, Sokol RJ, Martier SS, Ager JW, Kaplan MG. Maternal recall of 
alcohol, cocaine, and marijuana use during pregnancy. Neurotoxicology and Teratology. 1991; 
13:535–540. [PubMed: 1758408] 
24. Ostrea EM Jr. Knapp DK, Tannenbaum L, Ostrea AR, Romero A, Salari V, et al. Estimates of 
illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. 
Journal of Pediatrics. 2001; 138:344–348. [PubMed: 11241040] 
25. R Development Core Team. R: a language and environment for statistical computing. Vienna: 
2010. 
26. Ahrens K, Yazdy MM, Mitchell AA, Werler MM. Folic acid intake and spina bifida in the era of 
dietary folic acid fortification. Epidemiology. 2011; 22:731–737. [PubMed: 21659881] 
27. Hutchins E, DiPietro J. Psychosocial risk factors associated with cocaine use during pregnancy: a 
case-control study. Obstetrics & Gynecology. 1997; 90:142–147. [PubMed: 9207829] 
28. El Marroun H, Tiemeier H, Jaddoe VWV, Hofman A, Mackenbach JP, Steegers EAP, et al. 
Demographic, emotional and social determinants of cannabis use in early pregnancy: the 
Generation R study. Drug and Alcohol Dependence. 2008; 98:218–226. [PubMed: 18606505] 
29. Mackenzie SG, Lippman A. An investigation of report bias in a case-control study of pregnancy 
outcome. American Journal of Epidemiology. 1989; 129:65–75. [PubMed: 2910073] 
30. Khoury MJ, James LM, Erickson JD. On the use of affected controls to address recall bias in case-
control studies of birth defects. Teratology. 1994; 49:273–281. [PubMed: 8073366] 
31. Greenland S, Gustafson P. Accounting for independent nondifferential misclassification does not 
increase certainty that an observed association is in the correct direction. American Journal of 
Epidemiology. 2006; 164:63–68. [PubMed: 16641307] 
32. Van Gelder MMHJ, van Rooij IALM, de Walle HEK, Roeleveld N, Bakker MK. Maternal recall of 
prescription medication use during pregnancy using a paper-and-pencil questionnaire: a validation 
study in the Netherlands. Drug Safety. 2013; 36:43–54. [PubMed: 23315295] 
van Gelder et al. Page 10
Paediatr Perinat Epidemiol. Author manuscript; available in PMC 2015 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
van Gelder et al. Page 11
Table 1
Studies that reported sensitivity values for interview data on cannabis use during pregnancy
Sensitivity
Authors
Source
population
Years of data
collection Reference
(No. true positives/
Total no. positives)
Frank et al.21 Boston, USA 1984–1986 Urine samples 0.76 (94/123)
Hingson et al.20 Boston, USA 1984 Urine samples 0.82 (23/28)
Jacobson et al.23 Detroit, USA NR Antenatal
interview
0.75 (44/59)
Ostrea et al.24 Detroit, USA NR Maternal hair +
meconium
0.58
Zuckerman et al.22 Boston, USA 1984–1987 Urine samples 0.74 (149/202)
NR: not reported.
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Table 2
Prior odds ratios (95% credible intervals) used in the outcome modelsa
Anencephaly PerimembranousVSD
Cleft lip ± 
cleft
palate1,2
Esophageal
atresia3,4 Hypospadias
5,6
Diaphragmatic
hernia3,7 Gastroschisis
8
Reported cannabis use in periconceptional period
 No 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference]
 Yes 1.0 [0.2, 5.0] 1.0 [0.2, 5.0] 1.0 [0.2, 5.0] 1.0 [0.2, 5.0] 1.0 [0.2, 5.0] 1.0 [0.2, 5.0] 1.0 [0.2, 5.0]
Maternal age at delivery9,10
 <25 years 1.5 [1.0, 2.3] 1.0 [0.5, 2.0] 1.2 [0.8, 1.8] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 3.5 [1.4, 9.0]
 25–34 years 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference]
 ≥35 years 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 1.6 [1.0, 2.6] 1.5 [1.0, 2.3] 1.3 [0.7, 2.4] 0.4 [0.2, 0.8]
Race or ethnicity11-13
 NH white 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference]
 NH black 0.9 [0.6, 1.4] 0.9 [0.4, 2.0] 0.8 [0.4, 1.6] 0.8 [0.4, 1.6] 0.7 [0.5, 1.0] 0.9 [0.5, 1.6] 0.6 [0.3, 1.2]
 Hispanic 1.4 [1.0, 2.0] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 0.9 [0.5, 1.6] 0.6 [0.4, 1.0] 0.9 [0.5, 1.6] 1.0 [0.5, 2.0]
 Other 1.0 [0.2, 5.0] 1.0 [0.2, 5.0] 1.0 [0.2, 5.0] 1.0 [0.2, 5.0] 0.9 [0.5, 1.6] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0]
Level of education
 ≤12 years 1.3 [0.9, 1.9] 1.0 [0.2, 5.0] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 1.3 [0.7, 2.4]
 >12 years 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference]
Cigarette smoking in periconceptional period15
 No 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference]
 Yes 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 1.4 [1.0, 2.0] 1.0 [0.5, 2.0] 1.2 [0.7, 2.1] 1.0 [0.5, 2.0] 1.6 [1.0, 2.6]
Binge drinking in periconceptional period15
 No 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference]
 Yes 1.0 [0.2, 5.0] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 1.0 [0.2, 5.0] 1.0 [0.5, 2.0] 1.0 [0.2, 5.0]
Prepregnancy BMI16,17
 <30 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference]
 ≥30 1.4 [1.0, 2.0] 1.1 [0.6, 2.0] 1.2 [0.8, 1.8] 1.2 [0.9, 1.6] 1.1 [0.7, 1.7] 1.3 [0.9, 1.9] 0.2 [0.1, 0.4]
Periconceptional folic acid use18
 No 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference]
 Yes 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0] 1.0 [0.5, 2.0]
VSD, ventricular septal defect.
a
The key studies (see Appendix S1 for complete reference) that were used to help inform prior knowledge are indicated in superscript.
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Table 3
Observed adjusted odds ratios (aORs) and 95% confidence intervals (95% CIs) for the associations between 
periconceptional cannabis use and selected birth defects. Data from the National Birth Defects Prevention 
Study (NBDPS), 1997–2005
Birth defect
NBDPS 1997–2003a NBDPS 1997–2005
No. of exposed cases /
Total no. of cases aOR [95% CI]b
No. of exposed cases /
Total no. of cases aOR [95% CI]b
None [controls] 189/4866 1.0 [Reference] 251/6556 1.0 [Reference]
Anencephaly/craniorachischisis 12/244 1.7 [0.9, 3.4] 18/329 2.2 [1.3, 3.7]
Spina bifida 20/525 1.0 [0.6, 1.6] 24/703 0.9 [0.6, 1.4]
Anotia, microtia 11/287 1.0 [0.5, 2.0] 13/394 0.9 [0.5, 1.7]
D-transposition great vessels 9/336 0.7 [0.3, 1.4] 14/451 0.8 [0.5, 1.5]
Tetralogy of Fallot 19/486 1.1 [0.6, 1.8] 24/657 1.1 [0.7, 1.7]
Hypoplastic left heart 7/247 0.7 [0.3, 1.6] 10/355 0.8 [0.4, 1.5]
Coarctation of the aorta 15/433 1.0 [0.6, 1.8] 21/618 1.2 [0.7, 1.9]
Pulmonary valve stenosis 24/582 1.2 [0.8, 1.9] 32/850 1.0 [0.7, 1.5]
Perimembranous VSD 34/927 0.9 [0.6, 1.4] 52/1363 1.0 [0.8, 1.4]
ASD secundum 31/943 0.7 [0.5, 1.0] 54/1465 0.8 [0.6, 1.1]
ASD not otherwise specified 14/288 1.2 [0.7, 2.2] 22/500 1.1 [0.7, 1.8]
Cleft lip ± cleft palate 61/1269 1.0 [0.7, 1.4] 82/1735 1.0 [0.8, 1.3]
Cleft palate 25/677 0.8 [0.5, 1.3] 38/907 1.0 [0.7, 1.5]
Esophageal atresia 12/329 1.2 [0.6, 2.2] 17/419 1.4 [0.8, 2.4]
Anorectal atresia 13/468 0.7 [0.4, 1.2] 19/605 0.8 [0.5, 1.3]
Hypospadiasc 20/924 0.7 [0.4, 1.2] 32/1291 0.8 [0.5, 1.2]
Transverse limb deficiency 14/315 1.1 [0.6, 2.0] 16/404 1.0 [0.6, 1.7]
Craniosynostosis 16/517 1.0 [0.5, 1.7] 21/786 0.8 [0.5, 1.3]
Diaphragmatic hernia 19/365 1.3 [0.8, 2.2] 25/498 1.4 [0.9, 2.2]
Gastroschisis 62/485 1.3 [0.9, 1.8] 82/688 1.2 [0.9, 1.7]
ASD, atrial septal defect; VSD, ventricular septal defect.
aAs reported by van Gelder et al.13
bAdjusted for maternal factors: age at delivery, race or ethnicity, level of education, cigarette smoking, binge drinking, prepregnancy BMI, and 
periconceptional folic acid use.
cOnly male control infants included (1997-2003: n = 2452, 4.1% exposed; 1997-2005: n = 3316, 4.1% exposed).
Paediatr Perinat Epidemiol. Author manuscript; available in PMC 2015 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
van Gelder et al. Page 14
Ta
bl
e 
4
Po
st
er
io
r o
dd
s r
at
io
s (
OR
s) 
wi
th 
95
% 
cre
dib
le 
int
erv
als
 (C
RI
s) 
for
 th
e a
sso
cia
tio
n b
etw
ee
n p
eri
co
nc
ep
tio
na
l c
an
na
bis
 us
e a
nd
 an
en
ce
ph
aly
, e
so
ph
ag
ea
l 
at
re
sia
, d
ia
ph
ra
gm
at
ic
 h
er
ni
a,
 a
nd
 g
as
tro
sc
hi
sis
, a
dju
ste
d f
or 
un
de
rre
po
rtin
g o
f th
e e
xp
osu
re 
usi
ng
 B
ay
esi
an
 m
eth
od
s. D
ata
 fr
om
 th
e N
ati
on
al 
Bi
rth
 
D
ef
ec
ts 
Pr
ev
en
tio
n 
St
ud
y,
 1
99
7–
20
05 An
en
ce
ph
al
y
Es
op
ha
ge
al
 a
tr
es
ia
D
ia
ph
ra
gm
at
ic
 h
er
ni
a
G
as
tr
os
ch
isi
s
Sc
en
ar
io
O
R
[9
5%
 C
RI
]
H
al
f w
id
th
ra
tio
a
O
R
[9
5%
 C
RI
]
H
al
f w
id
th
ra
tio
a
O
R
[9
5%
 C
RI
]
H
al
f w
id
th
ra
tio
a
O
R
[9
5%
 C
RI
]
H
al
f w
id
th
ra
tio
a
N
o 
co
rre
ct
io
n 
fo
r u
nd
er
re
po
rti
ng
1.
9
[1
.1,
 3.
2]
0.
54
1.
3
[0
.7,
 2.
1]
0.
53
1.
3
[0
.9,
 2.
1]
0.
45
1.
4
[1
.0,
 1.
9]
0.
30
N
on
-d
iff
er
en
tia
l u
nd
er
re
po
rti
ng
 
Se
ns
iti
vi
ty
 0
.8
0
2.
0
[1
.2,
 3.
4]
0.
55
1.
5
[0
.9,
 2.
4]
0.
53
1.
5
[0
.9,
 2.
3]
0.
46
1.
5
[1
.1,
 2.
1]
0.
32
 
Se
ns
iti
vi
ty
 0
.6
5
2.
1
[1
.2,
 3.
4]
0.
54
1.
6
[0
.9,
 2.
5]
0.
51
1.
7
[1
.1,
 2.
6]
0.
45
1.
6
[1
.2,
 2.
2]
0.
31
 
Se
ns
iti
vi
ty
 0
.5
0
2.
0
[1
.2,
 3.
3]
0.
52
1.
6
[0
.9,
 2.
5]
0.
50
1.
8
[1
.2,
 2.
7]
0.
43
1.
6
[1
.2,
 2.
2]
0.
30
D
iff
er
en
tia
l u
nd
er
re
po
rti
ng
 
Se
ca
se
s 
0.
80
; S
e c
o
n
tr
ol
s 
0.
75
1.
9
[1
.1,
 3.
2]
0.
54
1.
4
[0
.8,
 2.
3]
0.
53
1.
5
[0
.9,
 2.
2]
0.
45
1.
4
[1
.1,
 2.
0]
0.
32
 
Se
ca
se
s 
0.
80
; S
e c
o
n
tr
ol
s 
0.
70
1.
8
[1
.1,
 3.
1]
0.
54
1.
3
[0
.8,
 2.
2]
0.
53
1.
4
[0
.9,
 2.
1]
0.
46
1.
4
[1
.0,
 1.
9]
0.
32
 
Se
ca
se
s 
0.
65
; S
e c
o
n
tr
ol
s 
0.
60
2.
0
[1
.1,
 3.
2]
0.
53
1.
5
[0
.9,
 2.
4]
0.
50
1.
6
[1
.0,
 2.
4]
0.
44
1.
5
[1
.1,
 2.
1]
0.
31
 
Se
ca
se
s 
0.
65
; S
e c
o
n
tr
ol
s 
0.
55
1.
9
[1
.1,
 3.
0]
0.
52
1.
4
[0
.9,
 2.
3]
0.
50
1.
6
[1
.0,
 2.
4]
0.
45
1.
5
[1
.1,
 2.
0]
0.
31
Se
ns
iti
vi
ty
 n
ot
 e
xa
ct
ly
 k
no
w
n
2.
1
[1
.2,
 3.
6]
0.
59
1.
7
[1
.0,
 2.
9]
0.
57
1.
8
[1
.1,
 3.
0]
0.
52
1.
7
[1
.2,
 2.
3]
0.
35
Se
, s
en
sit
iv
ity
a
H
al
f w
id
th
 ra
tio
 =
 ((
up
pe
r l
im
it 9
5%
 C
RI
 - l
ow
er 
lim
it 9
5%
 C
RI
) /
 2)
 / O
R
Paediatr Perinat Epidemiol. Author manuscript; available in PMC 2015 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
van Gelder et al. Page 15
Table 5
Posterior odds ratios (ORs) with 95% credible intervals (CRIs) for the association between periconceptional 
cannabis use and hypospadias, perimembranous ventricular septal defects, and cleft lip ± cleft palate, adjusted 
for underreporting of the exposure using Bayesian methods. Data from the National Birth Defects Prevention 
Study, 1997–2005
Hypospadias Perimembranous VSD Cleft lip ± cleft palate
Scenario OR [95% CRI] Half width ratioa OR [95% CRI] Half width ratioa OR [95% CRI] Half width ratioa
No correction for 
underreporting
0.7 [0.5, 1.1] 0.41 1.0 [0.7, 1.3] 0.32 1.0 [0.8, 1.4] 0.28
Non-differential underreporting
 Sensitivity 0.80 0.8 [0.5, 1.1] 0.41 1.0 [0.7, 1.3] 0.33 1.1 [0.8, 1.4] 0.28
 Sensitivity 0.65 0.8 [0.5, 1.2] 0.40 1.0 [0.7, 1.3] 0.32 1.1 [0.9, 1.5] 0.28
 Sensitivity 0.50 0.8 [0.6, 1.2] 0.38 1.0 [0.8, 1.4] 0.32 1.2 [0.9, 1.6] 0.27
Differential underreporting
 Secases 0.80; Secontrols 0.75 0.7 [0.5, 1.1] 0.41 0.9 [0.7, 1.3] 0.33 1.0 [0.8, 1.3] 0.28
 Secases 0.80; Secontrols 0.70 0.7 [0.5, 1.0] 0.41 0.9 [0.6, 1.2] 0.33 1.0 [0.7, 1.3] 0.28
 Secases 0.65; Secontrols 0.60 0.8 [0.5, 1.1] 0.39 0.9 [0.7, 1.3] 0.33 1.1 [0.8, 1.4] 0.27
 Secases 0.65; Secontrols 0.55 0.7 [0.5, 1.1] 0.40 0.9 [0.7, 1.2] 0.32 1.0 [0.8, 1.4] 0.28
Sensitivity not exactly known 0.9 [0.6, 1.4] 0.46 1.0 [0.7, 1.4] 0.39 1.2 [0.9, 1.7] 0.34
Se, sensitivity; VSD, ventricular septal defect.
a
Half width ratio = ((upper limit 95% CRI - lower limit 95% CRI) / 2) / OR
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